Skip Page Header

Home > Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide in the framework of the Council Decision on new psychoactive substances.

European Monitoring Centre for Drugs and Drug Addiction. (2014) Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide in the framework of the Council Decision on new psychoactive substances. Luxembourg: Office for Official Publications of the European Communities.

[img]
Preview
PDF (Risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide) - Published Version
547kB

This report presents the data and findings of the risk assessment on the new psychoactive substance, 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide, that was conducted by the Scientific Committee of the EMCDDA. Concerns over this synthetic opioid in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

AH-7921 is a synthetic opioid analgesic with a unique chemical structure. AH-7921 has appeared recently on the illicit drug market typically as a white powder.

Another name of AH-7921 (7), used by Internet suppliers/retailers selling the substance, user websites and in the popular media, is ‘doxylam’. It is important to note that ‘doxylam’ can easily be confused with ‘doxylamine’ — sometimes abbreviated also as ‘doxylam’


Item Type
Report
Date
May 2014
Pages
55 p.
Publisher
Office for Official Publications of the European Communities
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page